Pharmacologic progress in higher-risk MDS: an uphill battle
Introduction: Myelodysplastic syndromes Myelodysplastic syndromes:
Myelodysplastic Syndromes (MDS)
The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials
Aside from allogeneic transplantation, the current standard-of-care approach for higher-risk myelodysplastic syndromes
Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study
The COMMANDS trial established luspatercept as a first-line treatment for anemia anemia:
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML
To improve the tolerability of posttransplant maintenance and outcomes despite poor-risk disease genetics, we conducted a phase 1 study of venetoclax venetoclax:
Furha Cossor, MD
Institution
Saint Lukes's
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Furha Cossor, MD, is a board-certified oncologist and hematologist with Saint Luke's Cancer Specialists. Dr. Cossor has a special interest in multiple myeloma, leukemia, lymphoma, myelodysplastic syndrome, and myeproliferative neoplasms.
Anand B. Karnad, MD
Institution
UT Health San Antonio MD Anderson Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
My career since completing my fellowship training in Hematology and Medical Oncology at Boston City Hospital has been devoted to being a clinician-educator passionate about clinical trials as the best option for care. I have led Divisions of Hematology-Oncology at ETSU and at UT Health San Antonio and have played leadership roles in the Cancer Centers at both institutions. My current career focus is on hematology (blood disorders) spanning classical (or benign) hematology and all related pre-malignant and malignant disorders of the blood, bone marrow, lymph nodes, and immune system.
Ludovica Marando, MD
Institution
Harris Health System at Baylor College of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Marando is a Hematologist in Houston, Texas. Dr. Marando is a dedicated hematologist who is passionate about understanding the mechanisms that govern somatic clonal mosaicism within the hematopoietic stem cell compartment and the factors that govern progression into overt myeloid neoplasms. I do firmly believe that a better understanding of these mechanisms can lead to a shift in treatment paradigms: prevention of deadly hematological cancers.
Satyajit Kosuri, MD
Institution
Duchossois Center for Advanced Medicine - Hyde Park
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
About
Satyajit Kosuri, MD, is a medical oncologist who treats adult patients with acute leukemia, myelodysplastic syndrome and myelofibrosis. He is an expert in stem cell transplantation (also known as bone marrow transplant) and leads the Graft-Versus-Host Disease (GVHD) Clinic, a program designed to prevent and treat GVHD, a complication of allogeneic stem cell transplant. His clinical research focuses on improving patient access to transplant through the use of alternative donor strategies and the use of novel immune therapies in these diseases. His main passion is guiding his patients through